Market Outlook
By 2032, the U.S. Respiratory Care Devices Market is expected to reach approximately USD 15.72 billion, expanding at a CAGR of 7.80% during the forecast period 2027–2032. The market stood at USD 10.02 billion in 2026, following historical values of approximately USD 8.18 billion in 2023, USD 8.77 billion in 2024, and USD 9.40 billion in 2025. Values in this report are expressed in USD billions.
The U.S. respiratory care devices industry sits at the intersection of acute hospital medicine, chronic disease management, sleep medicine, home healthcare, emergency care, pulmonary diagnostics, and durable medical equipment. Demand is supported by a substantial clinical burden of chronic obstructive pulmonary disease, asthma, obstructive sleep apnea, acute respiratory failure, pneumonia, neuromuscular respiratory impairment, and chronic hypoxemia. In 2024, 8.6% of U.S. adults and 6.5% of children were living with current asthma. Chronic lower respiratory diseases remained the fifth-leading cause-of-death category, accounting for more than 145,000 deaths.
COPD represents another durable source of respiratory equipment utilization. Diagnosed COPD prevalence among adults was 3.8% on an age-adjusted basis in 2023, while prevalence reached 10.5% among adults aged 75 years and older. The disease accounted for more than 141,000 deaths in 2023 and generates approximately USD 24 billion in annual medical costs among adults aged 45 years and older. This burden translates into recurring demand for oxygen concentrators, nebulizers, non-invasive ventilation, pulse oximetry, pulmonary function testing, airway clearance systems, and hospital respiratory support.
Sleep-disordered breathing creates a separate high-volume device ecosystem. Conventional U.S. estimates indicate that approximately 30 million Americans have obstructive sleep apnea, while newer epidemiological modeling using broader diagnostic criteria indicates that the potential adult burden could exceed 80 million. Underdiagnosis remains substantial. This creates a long runway for continuous positive airway pressure, auto-adjusting PAP, bilevel PAP, masks, humidification, home sleep testing, connected adherence monitoring, and replacement consumables.
The market is simultaneously shifting from episodic hospital respiratory support toward longitudinal, distributed respiratory care. Portable oxygen concentrators, compact ventilators, cloud-connected PAP systems, wearable pulse oximetry, home spirometry, high-flow therapy, smart nebulization, and digital adherence platforms are extending respiratory treatment outside intensive care units and pulmonary laboratories. Manufacturers that combine therapeutic equipment with monitoring, software, consumables, service infrastructure, and reimbursement support are gaining strategic advantage over companies selling isolated devices.
The historical market expanded as U.S. hospitals resumed normal respiratory procedure volumes, health systems replaced pandemic-era equipment, sleep therapy demand recovered, and home oxygen utilization remained structurally important. From 2027 onward, growth becomes increasingly dependent on home-based chronic disease management, sleep apnea diagnosis, portable therapy, connected devices, recurring accessories, and workflow-integrated hospital platforms rather than pandemic-driven ventilator demand.
Introduction
According to the U.S. Respiratory Care Devices Market Report, respiratory care is one of the most clinically diverse areas of the American medical device sector because products are used across nearly every level of care. A patient may first encounter respiratory technology through spirometry in a physician office, progress to nebulized medication or PAP therapy at home, require oxygen therapy during an exacerbation, and eventually receive non-invasive or invasive ventilation in an emergency department or intensive care unit. This continuum creates a market with both high-acuity capital equipment and high-frequency recurring consumables.
Therapeutic respiratory care devices form the largest product group and represented approximately 55.7% of U.S. respiratory care device revenue in 2025. This category includes PAP systems, ventilators, oxygen concentrators, nebulizers, humidification systems, respiratory support equipment, and related treatment platforms. The revenue model is attractive because capital devices create follow-on requirements for masks, circuits, tubing, filters, sensors, humidification chambers, cannulas, replacement components, and service.
Hospital respiratory care remains commercially significant. Hospitals continue to account for the largest share of respiratory device purchasing because ventilators, capnography, oxygen delivery systems, airway management products, high-flow systems, blood-gas-related monitoring, and respiratory disposables are essential to critical care, emergency medicine, anesthesia, surgery, neonatal care, and inpatient pulmonary medicine. Hospitals represent approximately two-thirds of market demand under broad end-user classifications, although home-based care is expanding faster.
Respiratory care economics differ substantially from many implantable medical device markets. Buyers are frequently evaluating not only acquisition price but also uptime, reusable-versus-disposable economics, staff training, infection-control workflow, maintenance, service contracts, alarm burden, interoperability, consumable standardization, patient adherence, and reimbursement documentation. For hospital systems with multiple facilities, enterprise respiratory purchasing can involve hundreds or thousands of devices and a much larger recurring consumables opportunity.
Home care creates a different procurement environment. Medicare covers medically necessary respiratory durable medical equipment under defined eligibility and documentation rules. CPAP therapy can be covered initially through a 12-week trial for eligible patients with obstructive sleep apnea, while equipment is generally rented through Medicare’s capped-rental framework before ownership transfers after continuous rental requirements are met. Oxygen equipment, respiratory assist devices, nebulizers, and home ventilators similarly operate inside documentation-intensive reimbursement systems.
This reimbursement architecture makes compliance capability commercially important. Medicare’s 2024 fee-for-service data showed an improper payment rate of approximately 12.5% for CPAP devices and accessories, corresponding to more than USD 0.146 billion in projected improper payments. Oxygen equipment and supplies carried an improper payment rate of 11.3%, representing approximately USD 0.081 billion. For manufacturers and DME suppliers, documentation quality, physician ordering workflow, patient adherence records, and digital connectivity therefore have direct economic importance.
From 2027 through 2032, the strongest respiratory device vendors will increasingly compete through integrated care pathways. The winning model will connect diagnosis, device initiation, patient education, adherence monitoring, recurring supplies, clinical escalation, and outcome tracking. This is particularly relevant in sleep apnea, COPD, chronic oxygen therapy, and home non-invasive ventilation, where lifetime customer economics can materially exceed the initial hardware sale.
Key Market Drivers: What’s Fueling the U.S. Respiratory Care Devices Market Boom?
The first major driver is the scale and persistence of chronic respiratory disease. Approximately 27.8 million Americans were living with current asthma in 2023, including roughly 23.0 million adults and 4.8 million children. Asthma also generates approximately 1.4 million emergency department visits in a recent reporting year. This produces demand across nebulization, inhalation therapy, peak-flow monitoring, pulmonary function testing, oxygen monitoring, emergency respiratory care, and hospital-based escalation.
COPD provides an even more device-intensive chronic care pathway. The condition becomes substantially more prevalent with age, increasing from less than 1% among younger adults to more than 10% among Americans aged 75 years and older. Patients with moderate-to-severe COPD frequently require combinations of nebulized therapy, pulse oximetry, portable or stationary oxygen, non-invasive ventilation, pulmonary rehabilitation support, and repeated pulmonary function testing. This creates recurring demand rather than a one-time device event.
A second driver is the enormous unresolved sleep apnea population. Even the more conservative U.S. burden estimates indicate approximately 30 million affected individuals, with the majority historically remaining undiagnosed. Because PAP treatment generates an installed base that requires ongoing masks, tubing, filters, humidification components, monitoring, replacement devices, and adherence management, expanding diagnosis creates a multiyear revenue stream rather than a single equipment sale.
A third driver is migration toward home-based respiratory care. Portable oxygen concentrators, compact non-invasive ventilators, home PAP systems, handheld nebulizers, and connected diagnostic technologies allow clinically appropriate patients to receive care outside hospitals. This aligns with U.S. payer and health-system objectives to reduce avoidable inpatient utilization, shorten hospital stays, improve discharge pathways, and support chronic disease management in lower-cost environments.
Portable oxygen technology is particularly important. The U.S. oxygen concentrator market generated approximately USD 1.15 billion in 2023 and is projected to exceed USD 1.62 billion by 2030. Portable concentrators represented more than half of category revenue in the earlier benchmark year and continue to outperform fixed systems because they support mobility, travel, outpatient management, and patient independence.
A fourth driver is the replacement and modernization cycle inside hospitals. U.S. hospitals purchased large respiratory equipment volumes during the COVID-19 era, but replacement decisions are now increasingly based on normal capital planning, fleet standardization, cybersecurity, connectivity, clinical usability, and service economics. Ventilator demand is consequently moving from emergency capacity expansion toward technology refresh and fleet optimization. The U.S. ventilator category generated approximately USD 1.07 billion in 2023 and is on track to reach approximately USD 1.25 billion by 2030.
A fifth driver is growth in diagnostic intensity. Earlier identification of COPD, asthma, restrictive lung disease, respiratory impairment, and sleep-disordered breathing increases demand for spirometry, polysomnography, home sleep testing, pulse oximetry, capnography, gas analysis, and connected respiratory monitoring. The U.S. spirometer market illustrates this dynamic, with revenue moving from approximately USD 0.39 billion in 2022 toward USD 0.81 billion by 2030, reflecting one of the stronger growth profiles among conventional respiratory diagnostics.
A sixth driver is reimbursement-linked technology adoption. Connected PAP devices that automatically transmit adherence information, oxygen systems that simplify utilization monitoring, and remote respiratory devices that generate longitudinal patient data reduce administrative friction for providers and suppliers. Devices that improve documentation quality can therefore create economic value independently of their direct clinical performance.
Finally, respiratory care is becoming increasingly relevant to integrated health-system population management. COPD exacerbations, pneumonia, asthma attacks, sleep apnea-associated cardiovascular risk, and respiratory failure are expensive events. Technologies that enable earlier intervention or move appropriate treatment outside the hospital can support reduced acute utilization. This makes respiratory devices increasingly relevant to value-based care rather than only procedural or equipment budgets.
Innovation in Focus: How Manufacturers Are Raising the Bar?
Innovation in the U.S. respiratory care devices market is increasingly focused on making complex therapy easier to deliver, easier to monitor, and easier for patients to use consistently. The competitive advantage is moving away from airflow generation or oxygen production alone and toward connected ecosystems that improve initiation, adherence, clinical visibility, mobility, and service efficiency.
Positive airway pressure systems demonstrate this transition. Newer platforms use automatic pressure adjustment, personalized comfort settings, cellular or wireless data transmission, cloud-based patient management, simplified setup, leak detection, remote troubleshooting, and adherence analytics. These capabilities are commercially meaningful because treatment efficacy depends on repeated nightly use. A technologically advanced PAP platform that patients abandon has limited clinical and economic value.
Personalization is therefore becoming an important differentiator. PAP companies are developing systems that adapt pressure profiles and comfort parameters to individual breathing patterns. User interfaces are being simplified, while software enables clinicians and DME providers to identify poor adherence before a patient fails reimbursement requirements. Remote support reduces unnecessary in-person interventions and improves the economics of managing large installed patient populations.
Portable oxygen concentrators represent another innovation-intensive category. Improvements in compressor efficiency, molecular sieve performance, battery density, noise reduction, weight, pulse-dose algorithms, and connectivity are allowing patients to remain mobile while receiving prescribed oxygen. Portable concentrators represented approximately 56.8% of U.S. oxygen concentrator revenue in a recent benchmark year, underlining how strongly the market values mobility.
Ventilator innovation is increasingly centered on adaptability across care settings. Hospitals are evaluating systems that can support invasive and non-invasive ventilation, sophisticated lung-protective modes, neonatal or pediatric needs where appropriate, automated weaning support, high-flow functionality, and transport. Procurement committees favor platforms that can reduce the number of different device families requiring training and service.
High-flow nasal therapy is also expanding the respiratory support continuum between conventional oxygen therapy and more intensive ventilation. Its clinical use has increased because the technology can deliver warmed and humidified high-flow gas while allowing patients to eat, speak, and interact more naturally than with some mask-based modalities. Manufacturers are extending high-flow technologies into emergency, inpatient, post-acute, and selected home applications.
Nebulizer innovation is shifting from traditional compressor technology toward smaller mesh devices. The U.S. nebulizer category generated approximately USD 0.29 billion in 2023 and is positioned to exceed USD 0.41 billion by 2030. Mesh platforms can offer quieter operation, improved portability, shorter administration times, and reduced residual medication compared with conventional systems, making them particularly attractive for home and pediatric use.
Humidification remains an underappreciated component of respiratory workflow. The U.S. respiratory humidifier category generated approximately USD 0.20 billion in 2023 and is projected to approach USD 0.27 billion by 2030. Heated and integrated humidification improves patient tolerance of PAP, high-flow therapy, oxygen delivery, and mechanical ventilation and can reduce airway drying during prolonged treatment.
Monitoring technologies are increasingly converging with therapy. Pulse oximetry, capnography, respiratory rate monitoring, gas analysis, and connected sensors enable clinicians to identify hypoxemia, hypoventilation, airway obstruction, or deterioration earlier. The economic opportunity is moving toward platforms that combine measurements with actionable alerts and integrate into electronic medical records rather than stand-alone displays.
Artificial intelligence will primarily add value through workflow rather than replace respiratory clinicians. Algorithms can prioritize high-risk home patients, identify adherence deterioration, detect abnormal breathing patterns, support ventilator management, interpret sleep studies, and triage large remote-monitoring populations. The commercial winners will be solutions that reduce clinician workload while maintaining transparent clinical decision-making.
Segmentation Insights
The U.S. Respiratory Care Devices Market is segmented on the basis of product category, disease indication, end user, technology type, device mobility and care environment, and geography.
- By Product Category
Therapeutic Respiratory Care Devices
Therapeutic respiratory care devices represent the largest revenue category, accounting for approximately 55.7% of the U.S. market in 2025. The segment includes PAP systems, mechanical ventilators, oxygen concentrators, nebulizers, humidifiers, inhalation systems, resuscitation equipment, and other active respiratory therapy platforms.
Its commercial strength is driven by the combination of acute-care necessity and chronic repeat usage. Respiratory therapeutic devices are used across intensive care, emergency medicine, surgery, pulmonary medicine, sleep medicine, long-term care, and the home.
Positive Airway Pressure Devices
PAP devices include CPAP, APAP, and bilevel systems. CPAP remains the volume foundation of sleep apnea therapy, while APAP increasingly supports automated pressure titration and bilevel platforms address patients requiring differentiated inspiratory and expiratory pressures or more advanced ventilatory support.
North America generated more than USD 1.16 billion from PAP respiratory devices in 2023, with the United States representing the region’s dominant country market. CPAP accounted for roughly two-thirds of regional PAP revenue, while bilevel PAP has been one of the more attractive higher-growth subsegments.
The U.S. opportunity is driven less by simple device replacement than by diagnostic expansion, underpenetrated OSA treatment, masks and accessories, data services, patient engagement, and recurring replacement cycles.
Ventilators
Ventilators include advanced ICU systems, mid-range critical-care platforms, basic ventilators, neonatal and pediatric systems, transport ventilators, and selected home-use systems. The U.S. ventilator market generated approximately USD 1.07 billion in 2023 and is projected to reach about USD 1.25 billion by 2030.
ICU systems remain the highest-value portion because sophisticated ventilation, monitoring, alarm management, and integration are essential for high-acuity patients. Portable and transport ventilators provide stronger growth opportunities as respiratory support extends into emergency medical services, interfacility transport, home ventilation, and disaster preparedness.
Oxygen Concentrators and Oxygen Delivery Devices
Oxygen therapy represents one of the most economically important respiratory care categories. U.S. oxygen concentrator revenue reached approximately USD 1.15 billion in 2023 and is projected to surpass USD 1.62 billion by 2030. Portable systems represented approximately 56.8% of category revenue in the benchmark year.
The broader U.S. oxygen delivery device category, including oxygen masks, nasal cannulas, Venturi masks, non-rebreather masks, bag-valve masks, and PAP interfaces, generated approximately USD 2.50 billion in 2023 and is projected to approach USD 4.32 billion by 2030, reflecting an approximately 8.1% growth trajectory.
Portable oxygen concentrators are commercially attractive because they can reduce dependence on cylinder logistics and improve mobility, although clinical suitability depends on individual flow requirements.
Nebulizers
Nebulizers include jet, compressor-based, mesh, ultrasonic, and portable handheld technologies. U.S. category revenue was approximately USD 0.29 billion in 2023 and is expected to approach USD 0.41 billion by 2030.
Compressor-based devices retain substantial installed demand because of affordability and physician familiarity, while mesh and compact handheld systems are expanding faster in home care because they are smaller, quieter, and easier to transport.
COPD and asthma remain core clinical indications, although nebulization is also used in cystic fibrosis, bronchiectasis, and other pulmonary conditions requiring aerosolized medication.
Humidifiers
Respiratory humidifiers include heated, passover, integrated, built-in, and stand-alone configurations. U.S. category revenue reached approximately USD 0.20 billion in 2023, with heated humidifiers representing the largest product type.
Growth is closely linked to PAP adoption, high-flow respiratory therapy, oxygen delivery, and mechanical ventilation. Humidification has a direct role in patient comfort and can therefore influence therapy persistence, particularly in chronic PAP users.
Diagnostic and Monitoring Devices
Diagnostic respiratory devices include spirometers, peak-flow meters, polysomnography equipment, home sleep diagnostic systems, gas analyzers, pulmonary function testing platforms, and selected respiratory diagnostic technologies. Monitoring includes pulse oximetry, capnography, respiratory-rate monitoring, sensors, and multiparameter systems.
The U.S. spirometer category is projected to nearly double from approximately USD 0.39 billion in 2022 to USD 0.81 billion by 2030, reflecting stronger screening, pulmonary follow-up, occupational testing, and digital respiratory assessment.
Pulse oximetry remains one of the most widely deployed monitoring technologies across hospitals, clinics, home care, EMS, and consumer-facing health devices. Premium medical-grade systems compete increasingly through accuracy during motion and low perfusion rather than simple SpO2 measurement.
Consumables and Accessories
Masks, breathing circuits, nasal cannulas, filters, tubing, tracheostomy components, disposable resuscitators, humidification chambers, sensors, and replacement interfaces create an important recurring revenue pool.
This segment often carries attractive lifetime economics because a durable device may remain installed for several years while interfaces and consumables require repeated replacement. PAP masks, oxygen cannulas, circuits, filters, and sensors are particularly important recurring categories.
- By Disease Indication
Chronic Obstructive Pulmonary Disease
COPD represents the largest disease-indication opportunity within the U.S. respiratory care device ecosystem because of its chronic nature, aging-heavy patient profile, exacerbation frequency, and reliance on multiple respiratory technologies.
In 2023, age-adjusted diagnosed COPD prevalence among U.S. adults was 3.8%. Prevalence increased sharply with age, reaching 7.4% among adults aged 55–64, 8.9% among adults aged 65–74, and 10.5% among adults aged 75 years and older. COPD produced more than 141,000 deaths in 2023 and approximately USD 24 billion in annual medical costs among adults aged 45 and older.
Patients with advanced disease can generate demand for oxygen concentrators, pulse oximetry, nebulizers, non-invasive ventilation, spirometry, airway-clearance products, and acute-care ventilation during exacerbations.
Obstructive Sleep Apnea
Sleep apnea is one of the strongest long-term growth opportunities because prevalence significantly exceeds diagnosed and treated disease. Approximately 30 million Americans are commonly recognized as having sleep apnea, while newer modeling has suggested that more than 80 million adults may meet OSA criteria depending on the methodology used.
PAP therapy remains the primary device-based treatment pathway and supports recurring revenue from CPAP, APAP, bilevel devices, masks, tubing, filters, humidifiers, monitoring platforms, and replacement programs.
The principal commercial constraint is not lack of disease burden but patient identification, adherence, comfort, and continued therapy. Companies capable of improving the entire patient journey therefore have a competitive advantage.
Asthma
Current asthma affects tens of millions of Americans. In 2023, approximately 27.8 million people had current asthma, including about 23.0 million adults and 4.8 million children. Adult prevalence remained approximately 8.6% in 2024, while childhood prevalence was approximately 6.5%.
Respiratory device utilization includes nebulizers, spirometers, peak-flow meters, pulse oximeters, emergency oxygen equipment, and hospital ventilation during severe exacerbations. Pediatric respiratory care is particularly sensitive to ease of use, device noise, treatment duration, portability, and caregiver usability.
Acute Respiratory Failure and Critical Care
Acute respiratory failure encompasses severe pneumonia, sepsis, trauma, postoperative complications, acute respiratory distress syndrome, neurological impairment, and other conditions requiring respiratory support.
This indication sustains demand for invasive ventilation, non-invasive ventilation, high-flow oxygen therapy, humidification, capnography, pulse oximetry, resuscitation devices, breathing circuits, and oxygen delivery products.
Revenue growth is slower than during the pandemic period, but the category remains strategically protected because critical-care respiratory equipment cannot be deferred during life-threatening illness.
Infectious Respiratory Disease
Respiratory viral infections, bacterial pneumonia, RSV, influenza, COVID-related complications, and other infectious conditions contribute to seasonal and episodic demand.
The commercial impact extends beyond ventilators. Oxygen delivery, pulse oximetry, nebulization, monitoring, high-flow therapy, disposable circuits, masks, filters, and humidification all experience utilization increases during respiratory infection surges.
Hospital buyers are maintaining more resilient respiratory equipment inventories than before the pandemic, although procurement is now managed through normalized capital budgets.
Other Respiratory and Neuromuscular Disorders
Additional indications include pulmonary fibrosis, bronchiectasis, cystic fibrosis, neuromuscular respiratory failure, restrictive lung disease, pulmonary hypertension-associated hypoxemia, and chronic respiratory insufficiency.
While these populations are individually smaller, treatment intensity can be high. Home ventilation, airway clearance, oxygen therapy, monitoring, and advanced respiratory support create meaningful per-patient economic value.
- By End User
Hospitals and Health Systems
Hospitals represent the largest end-user category and account for approximately 68% of U.S. respiratory care device demand under broad market classifications. Critical-care ventilators, oxygen systems, high-flow devices, capnography, respiratory monitoring, diagnostic platforms, humidification, and disposables are heavily concentrated in hospital environments.
Large integrated delivery networks increasingly standardize respiratory equipment across multiple hospitals to reduce training variation and improve service economics. Enterprise contracts can include capital systems, software, accessories, consumables, maintenance, and education.
Clinical preference remains important, but procurement decisions increasingly involve biomedical engineering, respiratory therapy leadership, infection prevention, supply chain, IT, cybersecurity, finance, and value-analysis committees.
Home Care Settings and DME Providers
Home care is the most strategically important growth setting. PAP therapy, long-term oxygen, portable concentrators, nebulizers, home ventilation, respiratory assist devices, and monitoring are increasingly managed outside hospitals.
Medicare’s durable medical equipment structure makes reimbursement competency essential. CPAP is typically initiated under defined coverage criteria and monitored for continued use. The recurring economics of masks, filters, tubing, oxygen accessories, and replacement equipment can make the home-care channel commercially attractive.
Companies that can reduce setup time, automate adherence reporting, facilitate resupply, and remotely identify patients requiring intervention can improve both provider economics and patient persistence.
Ambulatory Surgery Centers and Outpatient Facilities
Ambulatory surgery centers require oxygen delivery, airway support, pulse oximetry, capnography, resuscitation equipment, and perioperative respiratory monitoring. Procedure migration to outpatient settings creates continued opportunity for compact equipment with low maintenance requirements and rapid turnover.
Outpatient pulmonary practices and specialty clinics also use spirometry, oximetry, nebulization, pulmonary diagnostic equipment, and sleep-related technologies.
Sleep Centers and Pulmonary Diagnostic Practices
Sleep laboratories and pulmonary function laboratories are important diagnostic gateways because they influence downstream therapeutic device initiation.
Home sleep testing continues to alter the economics of OSA diagnosis by reducing reliance on overnight laboratory polysomnography for appropriate patients. Pulmonary practices are similarly adopting more connected spirometry and monitoring technologies.
These customers prioritize diagnostic accuracy, software workflow, reimbursement support, integration, and efficient patient throughput.
Emergency Medical Services, Long-Term Care and Other Users
EMS providers require rugged transport ventilators, oxygen delivery, resuscitation products, portable suction, monitoring, and airway equipment. Reliability, battery life, weight, environmental durability, and fast setup are critical.
Long-term care and skilled nursing facilities represent a meaningful respiratory opportunity because of older patient populations, chronic pulmonary disease, oxygen dependence, tracheostomy care, and non-invasive ventilation.
- By Technology Type
Positive Airway Pressure and Non-Invasive Ventilation
CPAP, APAP, bilevel PAP, and other non-invasive pressure-support technologies form one of the market’s most attractive recurring ecosystems.
CPAP provides the largest installed patient base, while auto-titrating and bilevel technologies support premiumization. Connected therapy monitoring has transformed this category from a stand-alone device market into a data-enabled chronic-care platform.
Mechanical Ventilation
Mechanical ventilation includes invasive ICU ventilation, non-invasive hospital ventilation, transport ventilation, neonatal ventilation, and home ventilatory support.
The technology is mature, but differentiation continues through lung-protective modes, closed-loop assistance, enhanced monitoring, improved interfaces, smaller footprints, and interoperability.
Oxygen Generation and Delivery
The technology group includes stationary and portable concentrators, cylinders, oxygen-conserving systems, flow controllers, masks, cannulas, Venturi systems, high-flow interfaces, and related accessories.
The U.S. oxygen delivery device category’s approximately 8.1% growth trajectory through 2030 demonstrates stronger expansion than several mature capital-equipment categories.
Aerosol Therapy and Humidification
Nebulizers, aerosol delivery systems, humidifiers, and related accessories address chronic and acute respiratory treatment.
Mesh nebulization is moving aerosol treatment toward portability and quieter home use, while integrated heated humidification is becoming increasingly embedded in PAP, high-flow therapy, and ventilator ecosystems.
Respiratory Diagnostics, Monitoring and Connected Care
Spirometry, sleep diagnostics, pulse oximetry, capnography, gas analysis, respiratory sensors, and remote monitoring represent a rapidly strategic layer.
Growth is supported not only by clinical demand but by the need to manage large respiratory populations with limited specialist capacity. Connected systems allow clinicians to focus attention on patients showing deterioration rather than reviewing every stable patient manually.
- By Device Mobility and Care Environment
Fixed and Stationary Systems
Fixed devices include ICU ventilators, hospital respiratory platforms, pulmonary laboratory systems, bedside monitoring, stationary oxygen concentrators, and larger diagnostic installations.
This segment remains central to hospital procurement and favors manufacturers with established service infrastructure, high uptime, integration capability, and enterprise contracting.
Portable and Transportable Devices
Portable oxygen concentrators, transport ventilators, handheld spirometers, portable capnographs, compact nebulizers, and battery-powered respiratory equipment represent one of the clearest growth themes.
Portable oxygen concentrators already represent the majority of U.S. concentrator category revenue by product mix. Mobility improves quality of life and expands use across travel, ambulatory care, rehabilitation, emergency transport, and home health.
Home-Connected Devices
Connected PAP systems, home ventilators, remote oximetry, digitally enabled nebulization, and app-linked respiratory diagnostic devices support longitudinal management.
The key commercial value is not simply connectivity. Manufacturers must convert data into actionable workflow for physicians, respiratory therapists, DME providers, and patients.
Disposable Interfaces and Recurring Supplies
Disposable masks, circuits, cannulas, filters, sensors, tubing, tracheostomy products, and related supplies create recurring demand across all care environments.
The category is particularly important in infection control and in sustaining revenue after capital equipment placement.
Regional Insights: Where the Market is Growing Fastest
The U.S. Respiratory Care Devices Market is geographically segmented into the South, Northeast, Midwest, and West. Regional demand differs materially based on COPD prevalence, asthma burden, smoking history, age distribution, hospital density, sleep medicine infrastructure, urbanization, DME penetration, specialist availability, payer mix, and migration patterns.
The South represents the largest overall commercial opportunity, while the West is positioned for the strongest technology-led expansion. The Northeast remains a high-value market for advanced clinical adoption, and the Midwest combines significant chronic respiratory disease burden with mature health-system purchasing networks.
South
The South is the largest U.S. respiratory care region because it combines the country’s largest population concentration with a high burden of chronic pulmonary disease, rapidly growing states, substantial Medicare populations, and extensive hospital networks.
COPD prevalence illustrates the clinical opportunity. Adults in the South recorded an age-adjusted COPD prevalence of approximately 4.2%, materially above the approximately 3.1% recorded in the West. Rural and economically disadvantaged Southern populations experience particularly high COPD burden, creating demand for oxygen therapy, nebulization, portable monitoring, and scalable home respiratory care.
Texas is one of the country’s most important respiratory device markets because of its population size, large metropolitan hospital systems, extensive home-care network, and high absolute patient volumes. Approximately 1.97 million Texas adults were living with current asthma in 2023, representing roughly 8.5% of adults in the state. Texas also recorded more than half a million children with current asthma. Houston, Dallas-Fort Worth, Austin, and San Antonio support sophisticated pulmonary, sleep, critical-care, and pediatric respiratory markets.
Florida is structurally attractive because of its older population. Medicare exposure increases demand for oxygen concentrators, PAP systems, home ventilation, nebulizers, and monitoring. More than 1.55 million Florida adults were living with current asthma in 2023. The state’s large retirement population also supports high volumes of COPD and sleep apnea treatment.
North Carolina recorded approximately 0.86 million adults with current asthma, representing about 10.0% of adults. The Research Triangle, Charlotte, Winston-Salem, and major academic health systems support advanced respiratory diagnostics and critical-care technology.
Georgia recorded approximately 0.80 million adults with current asthma, while Virginia recorded almost 0.70 million. Virginia, Maryland, Tennessee, Louisiana, Oklahoma, and West Virginia also represent commercially important respiratory markets because of their combination of chronic disease burden and major regional health systems.
West Virginia is particularly notable from a disease-burden perspective: adult current asthma prevalence reached approximately 13.9%, among the highest reported state rates. This high burden, combined with rural access limitations, supports home oxygen, nebulization, portable diagnostics, and remote respiratory monitoring.
The commercial challenge in the South is geographic dispersion. Large academic and integrated health systems purchase advanced technology, while many rural markets need portable, serviceable, reimbursement-compatible devices. Manufacturers with strong distributor and DME networks can therefore outperform companies focused exclusively on major academic centers.
Northeast
The Northeast is smaller by population than the South but remains one of the highest-value respiratory device markets because of its concentration of academic medical centers, pulmonary specialists, pediatric hospitals, sleep centers, clinical research institutions, and sophisticated integrated health systems.
New York is the region’s largest state market. Approximately 1.55 million New York adults were living with current asthma in 2023, representing about 9.9% of the adult population. New York City and major upstate health systems provide substantial demand for ventilators, respiratory monitoring, sleep diagnostics, PAP therapy, and pulmonary testing.
Massachusetts is disproportionately influential because of its dense academic and life-sciences ecosystem. Approximately 672,000 adults in the state were living with current asthma, corresponding to about 11.9% adult prevalence. Boston-area hospitals frequently serve as early evaluators of advanced respiratory monitoring, neonatal technologies, critical-care ventilation, and digital pulmonary platforms.
Maine reported adult current asthma prevalence of approximately 12.9%, while New Hampshire recorded around 11.8%, Rhode Island 12.2%, and Vermont 11.2%. These relatively high rates are relevant to home respiratory therapy and chronic disease management.
The Northeast’s age-adjusted adult COPD prevalence was approximately 3.4%, below the South and Midwest. However, lower population-level prevalence does not translate directly into lower device value because the region has high procedure intensity, specialist density, premium technology adoption, and major tertiary-care institutions.
Hospital procurement in the Northeast is typically evidence-driven. Vendors are expected to demonstrate clinical reliability, interoperability, cybersecurity, service capability, health economic value, and measurable workflow improvement. Premium systems can achieve strong adoption when supported by convincing evidence.
The region is also strategically important for sleep medicine and digital health. High specialist concentration and dense healthcare networks make it attractive for remote PAP management, home diagnostics, connected spirometry, and chronic respiratory population-management programs.
Midwest
The Midwest represents a stable and clinically significant respiratory care market. Adult COPD prevalence reached approximately 4.2%, matching the South and exceeding both the Northeast and West. This supports substantial utilization of oxygen therapy, nebulization, pulmonary diagnostics, non-invasive ventilation, and hospital respiratory care.
Ohio is a major respiratory device market with approximately 1.01 million adults living with current asthma, corresponding to about 11.0% adult prevalence. The state includes several nationally prominent health systems with strong pulmonary, sleep, critical-care, and pediatric capabilities.
Michigan recorded approximately 869,000 adults with current asthma, also representing about 11.0% prevalence. Detroit and major regional hospital networks create substantial demand for acute respiratory support as well as chronic home-care technology.
Illinois recorded approximately 937,000 adults with current asthma, while Indiana had approximately 605,000 adults and one of the higher prevalence rates at about 11.5%. Wisconsin recorded approximately 504,000 adults with current asthma, while Minnesota, Missouri, Iowa, Kansas, Nebraska, and the Dakotas provide additional regional demand.
The Midwest has particular strategic relevance for COPD because of its chronic disease burden and large nonmetropolitan population. In U.S. adults aged 45 and older, COPD prevalence is substantially higher outside major metropolitan markets. Nonmetropolitan prevalence reached approximately 10.6% among adults aged 45 and older in 2024 and approximately 14.0% among those aged 65 years and older.
This creates a strong use case for home oxygen, portable concentrators, connected monitoring, tele-respiratory care, and regional referral models.
The Midwest is also important for medical technology manufacturing and clinical expertise. Minnesota in particular retains a substantial medtech ecosystem, while Chicago, Cleveland, Columbus, Detroit, Indianapolis, Milwaukee, and Minneapolis-St. Paul are significant respiratory-care purchasing centers.
Manufacturers generally succeed in this region by combining strong clinical education with reliable field service and disciplined contracting. Total ownership cost can be especially important for community hospital systems facing capital pressure.
West
The West is positioned to be the fastest-growing respiratory device region through 2032 because of population growth, strong technology adoption, digital-health infrastructure, high concentration of innovative providers, and rapid uptake of connected home-care models.
Regional COPD prevalence is comparatively lower at approximately 3.1%, but the West includes several of the country’s largest and fastest-growing state markets.
California dominates the region by absolute market size. Approximately 2.69 million California adults were living with current asthma in 2023, despite an adult prevalence of about 8.8%. The state’s enormous population, major hospital systems, medtech ecosystem, and early digital-health adoption make it a critical launch market for connected respiratory platforms.
California is especially attractive for home sleep testing, digital PAP engagement, advanced critical-care technology, remote patient monitoring, and portable oxygen systems. Major provider markets include Los Angeles, San Diego, San Francisco Bay Area, Sacramento, and Orange County.
Washington recorded approximately 660,000 adults with current asthma, representing roughly 10.7% prevalence. Seattle’s technology ecosystem and integrated health systems create favorable conditions for cloud-based respiratory monitoring and virtual care.
Arizona had approximately 601,000 adults with current asthma, representing about 10.3% prevalence. Its rapidly expanding and aging population makes the state increasingly important for oxygen therapy, sleep apnea treatment, COPD care, and home respiratory equipment.
Colorado reported adult current asthma prevalence of approximately 11.3%, while Oregon recorded about 11.8%, Utah 11.0%, and Montana 11.7%. These states represent attractive opportunities for portable equipment because geography, active lifestyles, and rural populations increase the value of mobility and remote monitoring.
The West is likely to gain share as respiratory care becomes increasingly consumer-friendly, portable, and digitally connected. Device companies that can integrate hardware with apps, cloud platforms, virtual support, and home delivery are particularly well positioned.
Key Market Players
The U.S. Respiratory Care Devices competitive landscape is moderately consolidated in therapeutic devices but fragmented across diagnostics, accessories, oxygen therapy, home-care equipment, monitoring, and specialty ventilation.
Some of the highly relevant players operating in the U.S. respiratory care devices industry are:
ResMed Inc.
Koninklijke Philips N.V. / Philips Respironics
Medtronic plc
Fisher & Paykel Healthcare Corporation Limited
GE HealthCare Technologies Inc.
Masimo Corporation
Inogen, Inc.
Baxter International Inc.
ICU Medical, Inc.
Drägerwerk AG & Co. KGaA
ZOLL Medical Corporation
Hamilton Medical
Drive DeVilbiss Healthcare
Teleflex Incorporated
React Health
ResMed is particularly strong in sleep-disordered breathing and connected home respiratory care, supported by PAP devices, masks, digital adherence platforms, and extensive patient-data infrastructure. The strategic value of its installed base extends beyond equipment revenue because therapy management and recurring accessories create significant lifetime patient economics.
Philips Respironics historically represented one of the largest respiratory and sleep therapy competitors. Its competitive position has been materially affected by the large CPAP and ventilator recall and subsequent U.S. regulatory restrictions, creating opportunities for competitors in PAP, masks, ventilation, and home respiratory equipment.
Medtronic maintains strategic relevance through airway management, respiratory monitoring, capnography, pulse oximetry, and acute-care technologies. Fisher & Paykel Healthcare is a major competitor in humidification, interfaces, high-flow nasal therapy, and respiratory consumables.
Inogen is one of the most visible companies focused on portable oxygen concentration and benefits from the structural shift toward patient mobility. Drive DeVilbiss Healthcare participates across oxygen equipment and home respiratory care, while React Health competes in PAP, ventilation, oxygen and sleep-related technologies.
ZOLL strengthened its respiratory position through the acquisition of selected Vyaire ventilator product lines, including bellavista, LTV, fabian, and 3100 HFOV. This expanded its presence beyond transport ventilation into broader hospital and neonatal respiratory support.
Masimo competes strongly in pulse oximetry and patient monitoring, while Baxter maintains respiratory health and diagnostic technologies through its broader connected-care portfolio. Hamilton Medical and Dräger remain important high-acuity ventilation competitors.
Competitive advantage through 2032 will increasingly depend on installed-base scale, recurring consumables, digital connectivity, regulatory execution, clinical evidence, field service, patient adherence, DME relationships, hospital contracting, and the ability to operate across multiple sites of care.
Recent Developments
The U.S. respiratory care device market has experienced significant competitive and regulatory change since 2024.
One of the most important events was the April 2024 federal consent decree involving Philips Respironics following its large recall of CPAP, BiPAP and ventilator products. The original recall affected approximately 15 million devices worldwide. The consent decree restricted, with limited exceptions, production and sale of certain new PAP and respiratory products from specified U.S. facilities until regulatory requirements are satisfied. The disruption materially altered competitive share opportunities in U.S. sleep therapy.
Consolidation also changed the ventilation landscape. In October 2024, ZOLL completed the acquisition of selected Vyaire Medical ventilator product lines following Vyaire’s Chapter 11 process. The acquired portfolio included bellavista, LTV, fabian and 3100 HFOV products, giving ZOLL broader exposure to adult critical care, transport, neonatal ventilation, and high-frequency oscillatory ventilation.
Product development in home sleep therapy has remained active. FDA records during 2025 and 2026 show ongoing clearances for PAP-associated devices and software. ResMed received clearance related to myAir in May 2025, personalized therapy comfort functionality later in 2025, ResScan Essentials in May 2026, and the Orion non-continuous ventilator platform in June 2026. These developments reinforce the shift toward connected, personalized, software-supported sleep therapy.
Oxygen therapy innovation also continues. DeVilbiss Healthcare received U.S. clearance in December 2025 for its PulmO2 10-liter oxygen concentrator. Additional portable oxygen concentrators have entered the regulatory pipeline, increasing competition around output capability, weight, battery efficiency, noise, portability, and service.
The regulatory environment is becoming more demanding in parallel. Respiratory devices must increasingly satisfy requirements related not only to mechanical and electrical safety but also software validation, cybersecurity, biocompatibility, connected-device risk, alarm performance, and usability. FDA recognition of updated respiratory equipment standards will influence new product submissions and design controls over the forecast period.
Hospital respiratory purchasing has meanwhile normalized from the pandemic period. Providers are no longer purchasing ventilator capacity at emergency scale. Instead, they are replacing aging fleets and standardizing around fewer platforms with stronger interoperability, service coverage, common accessories, and staff familiarity.
In the home market, digital engagement is becoming one of the primary battlegrounds. Manufacturers and DME suppliers are using remote adherence monitoring, automated resupply, patient apps, virtual coaching, and predictive analytics to reduce therapy abandonment. This is particularly important in sleep apnea because the commercial value of a PAP patient depends heavily on sustained device use.
Portable oxygen is similarly shifting from hardware competition toward service ecosystems. Lightweight equipment, battery management, online ordering, direct-to-consumer awareness, reimbursement support, and patient mobility are influencing brand selection.
Conclusion
The U.S. Respiratory Care Devices Market Size & Share is positioned to expand from USD 10.02 billion in 2026 to approximately USD 15.72 billion by 2032, supported by a 7.80% CAGR from 2027 to 2032. Historical market development from approximately USD 8.18 billion in 2023 to USD 9.40 billion in 2025 reflects normalization of hospital respiratory purchasing alongside continued structural growth in chronic disease management and home care.
The fundamental growth thesis is stronger than a simple increase in respiratory disease incidence. The market is undergoing a change in where care is delivered and how respiratory patients are managed. Hospitals will remain the dominant buyers of high-acuity ventilation, monitoring, and respiratory support, but home respiratory care will capture a growing portion of incremental value.
The most attractive opportunities through 2032 will include connected PAP therapy, portable oxygen concentrators, advanced non-invasive ventilation, high-flow respiratory therapy, mesh nebulization, connected spirometry, respiratory monitoring, remote adherence platforms, and recurring interfaces and consumables.
COPD will remain the most device-intensive chronic disease indication because of its progressive nature, high burden among older adults, repeated exacerbations, and dependence on oxygen and respiratory support. Sleep apnea offers the largest underdiagnosed population opportunity. Asthma provides a broad diagnostic and aerosol therapy base, while acute respiratory failure protects demand for hospital equipment.
Regional opportunity will remain strongest in the South because of population scale, chronic disease burden, rapid demographic growth, and Medicare exposure. Texas and Florida will be particularly important. The Northeast will remain influential in premium technology adoption and evidence generation. The Midwest offers a significant COPD and chronic disease opportunity, particularly outside major metropolitan areas. The West will lead technology-driven expansion in connected and home-based respiratory care.
For device manufacturers, investors, distributors, DME providers, and health-system decision makers, the key competitive question is therefore not simply how many respiratory devices will be purchased. The more important issue is which companies can own a larger portion of the respiratory patient pathway.
Companies that control diagnosis, therapy initiation, connected monitoring, patient engagement, recurring supplies, clinical escalation, and documentation have the opportunity to create substantially greater lifetime value than companies competing solely on hardware specifications.
Hospital buyers will increasingly favor platforms that reduce training burden, standardize consumables, integrate data, improve uptime, simplify maintenance, and support measurable clinical efficiency. Home-care buyers will prioritize adherence, reimbursement documentation, ease of setup, remote serviceability, patient comfort, and predictable resupply economics.
The U.S. respiratory care market is consequently evolving from a collection of discrete ventilators, PAP machines, oxygen systems, and diagnostic products into an integrated respiratory management ecosystem. Manufacturers capable of combining clinical effectiveness, workflow economics, patient usability, reimbursement compatibility, digital connectivity, and reliable service infrastructure will be positioned to capture the strongest share of market growth through 2032.